EMV Capital PLC EMVC

EMV Capital (AIM:EMVC) CEO Ilian Iliev spoke with Proactive's Stephen Gunnion about the company's first-half performance, growth in assets under management, portfolio developments and priorities for the remainder of 2026. Iliev said the first half was primarily about steadily executing EMVC's strategy, completing work developed in the final quarter of last year and positioning the company for further activity in H2. Discussing the portfolio, Iliev highlighted valuation movements across several companies and said EMVC was pleased that assets under management rose 4% during the first half. "We f

EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev spoke with Proactive's Stephen Gunnion about Project Winalot and how the Rotterdam facility could provide a route to commercial-scale deployment for DeepTech Recycling's technology. He was joined by DeepTech Recycling CEO Marvine Besong, who discussed the site's technical fit and its potential role as a reference facility for future projects. Iliev explained that EMV Capital and DeepTech Recycling had spent several years assessing locations and project opportunities to validate the technology at commercial scale. Rotterdam stood out because m

EMV Capital (AIM:EMVC, FRA:NTK1) has bought a Rotterdam plastics recycling plant for an undisclosed price through new subsidiary Winalot. It plans to retrofit new tech and get it running again within around 18 months. Pantheon Resources PLC (AIM:PANR, OTCQX:PTHRF) says new seismic work could lift its Kodiak oil resource estimate by at least 25%. Ten parties remain active in the data room as farm-out talks continue. MP Evans Group PLC (AIM:MPE) says its rising palm oil harvest has carried into the second half after a record first half. Gross profit jumped 25%, and the interim dividend's up 39%.

EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev and AMR Bio chair Nigel Brooksby joined Proactive's Stephen Gunnion to discuss progress on XF-73, the antimicrobial drug candidate advancing towards Phase 3, and the milestones that could define the company's next stage of growth. Iliev said EMV Capital is supporting AMR Bio through its Venture Build programme, combining financial backing with hands-on value creation, and believes the next nine to twelve months could represent an important inflection point for the asset. Brooksby outlined preparations for a Type B meeting with the FDA to disc

EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev and ProAxsis managing director Dr Louise Ryan Murphy joined Proactive's Stephen Gunnion to discuss the company's commercial transformation and the opportunity emerging from its Imperial College London COPD study. Iliev said EMV Capital has supported ProAxsis since its Queen's University Belfast spin-out, highlighting progress towards operational breakeven and a recent restructuring to broaden US investor access. Ryan Murphy explained that ProAxsis has repositioned as a commercial protease biomarker-led research company, providing kit sales, c

Galliford Try (LSE:GFRD) has secured a place on the £1.5 billion YORbuild Major Works 2 framework, covering public sector projects across Yorkshire, the North East and the Midlands. The appointment runs for four years across two project size categories. Itaconix (AIM:ITX) has extended its collaboration with Bonals Technologies until December 2028 to push plastic-free detergent tablets into the US and Canadian markets. The company says its 8-gram dish detergent tablet is already generating strong interest from purpose-driven brands. Quantum Blockchain Technologies (AIM:QBT) has produced the fir

Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF) is targeting uranium recovery from historic mine waste in Colorado's Uravan Belt with zero capex exposure, thanks to its partnership with DISA Technologies.  Gamma data is due by end of May and assay results by Q3, with a potential revenue stream emerging as early as mid-2027. Critical Mineral Resources PLC (LSE:CMRS, FRA:98J) is drilling copper intercepts averaging five metres at Agadir Melloul in Morocco — well above its two-metre target — with less than 3% of the area tested so far.  A maiden resource is targeted for Q3, with mine construction

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) has won £1.3 million of new contracts, including work to validate a blood-based Alzheimer's biomarker test for FDA clearance and an extended Huntington's disease trial. CEO Bram Goorden says the wins hit three key components of the company's growth strategy. Ilika PLC (AIM:IKA, OTCQX:ILIKF, FRA:I8A) has reported its first commercial revenue from its Stereax solid-state battery range after delivering an initial batch to US partner Cirtec Medical. The company is also expanding its larger Goliath battery into defence and consumer markets, including a joint

Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF, FRA:T2X) delivered a strong first quarter, with revenue up to $74.3 million and net income rising to $46.7 million as a gold price of $4,820 per ounce more than offset lower sales volumes. The company is on track for 75,000 to 85,000 ounces of production this year and is advancing toward a final investment decision at its Douta project in Senegal. IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) is guiding for at least 15% revenue growth this year after a strong first half, with revenue up 23% and its order book growing 38% to £18.1 million. A £10

EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev tells Proactive's Stephen Gunnion that the company delivered a strong 2025, with platform revenue reaching just over £3 million, up from zero when the current management team took over in 2025, and assets under management growing 15% to £112 million. Iliev says EMV Capital deliberately "leans in rather than backwards" during difficult markets, using dislocation to find opportunities across deep tech, life sciences, semiconductors, AI and energy efficiency. Portfolio highlights include AMR Bio's progress toward an FDA phase three application,

RC Fornax PLC (AIM:RCFX) finance director Rob Shepherd says the company is now a fundamentally different business. New hires in sales, tech, and governance are driving change, with revenue targeting just shy of £6 million for FY26. The order book is growing, and defence spending clarity could accelerate that further. HeLIX Exploration (AIM:HEX, OTCQB:HHEXF) just became the first helium producer in Montana. CEO Bo Sears says no other publicly listed helium explorer has hit production in just 22 months from IPO. Three wells are live, with offtake partners visiting the site in coming weeks. EMV C

EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev talked with Proactive's Stephen Gunnion about Vortex Biotech’s advancement in liquid biopsy technology and how the company fits within its "venture building" strategy. Iliev explained that Vortex addresses a significant public healthcare need in early cancer diagnostics, particularly as the industry shifts away from traditional tissue biopsies toward liquid biopsy approaches. He highlighted that tissue biopsies are often painful, costly, and limited in frequency, whereas liquid biopsies offer a less invasive and more scalable alternative. Vor

EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev talked with Proactive's Stephen Gunnion about the company’s investment strategy, portfolio performance and how EMV Capital continues to build value despite challenging global market conditions. Iliev explained that EMV Capital has maintained assets under management above £100 million in 2025, at a time when many venture funds have seen declines. He said this resilience reflects the strength of the company’s portfolio, which is focused on deep tech, life sciences, data and AI, all underpinned by strong fundamentals. According to Iliev, the int

Advantage NRG, part of Hercules PLC (LSE:HERC), has landed £6.5 million of contracted grid work across two UK networks. The deals run through 2026 and scale operations up to 52 skilled workers at peak. Tooru PLC (AIM:TOO, FRA:73N) says its gluten-free OAF brand will launch in ASDA stores from April 2026. The range is already in Tesco and is expanding fast as demand for free-from food grows. EMV Capital (AIM:EMVC, FRA:NTK1) says it’s well placed for a capital markets recovery despite quiet exits. Assets topped £100 million at the end of last year and several portfolio companies are now in M&A d